

RealRate

PHARMACEUTICAL 2021











RealRate

PHARMACEUTICAL 2021

Altimmune Inc. Rank 44 of 402



The relative strengths and weaknesses of Altimmune Inc. are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Altimmune Inc. compared to the market average is the variable Assets, Current, increasing the Economic Capital Ratio by 65% points. The greatest weakness of Altimmune Inc. is the variable Other Revenues, reducing the Economic Capital Ratio by 11% points.

The company's Economic Capital Ratio, given in the ranking table, is 257%, being 209% points above the market average of 47%.

Input Variable	Value in 1000 USD
Assets, Current	230,257
Cost of Goods Sold	0
Intangible Assets	12,824
Liabilities, Current	12,020
Liabilities, Non-Current	0
Other Assets	977
Other Compr. Net Income	-24
Other Expenses	-5,417
Other Liabilities	7,218
Other Net Income	337
Other Revenues	8,185
Property and Equipment	1,057
Research and Development	49,774
Selling, General and Administrative Expense	13,209

Output Variable	Value in 1000 USD
Assets	245,115
Liabilities	19,239
Expenses	57,567
Revenues	8,185
Stockholders Equity	225,876
Net Income	-49,044
Comprehensive Net Income	-49,057
Economic Capital Ratio	257%

